Stonepine Capital Fully Exits ANI Pharmaceuticals, Reflecting $2.52 Million Loss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 28 2025
0mins
Should l Buy ANIP?
Source: Fool
- Position Change: Stonepine Capital reported in its latest SEC filing that it fully exited its position in ANI Pharmaceuticals, selling 38,597 shares for a total transaction value of $2.52 million, indicating a cautious outlook on the company's future performance.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has surged 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase, showcasing the company's strong market presence.
- Financial Overview: ANI Pharmaceuticals boasts a market capitalization of $1.85 billion, with trailing twelve-month revenue of $826.89 million and net income of $40.57 million, reflecting the company's sustained profitability in the specialty pharmaceuticals sector.
- Future Outlook: Management has raised full-year revenue guidance to $873 million, with rare disease therapies expected to drive approximately half of total sales by 2025, highlighting the company's growth potential in niche therapeutic areas.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANIP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANIP
Wall Street analysts forecast ANIP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIP is 109.75 USD with a low forecast of 100.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 81.500
Low
100.00
Averages
109.75
High
121.00
Current: 81.500
Low
100.00
Averages
109.75
High
121.00
About ANIP
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
S&P 500 Hits Record High as Data Storage Stocks Lead Gains
- Market Recovery: The S&P 500 index rose by 0.16% to reach a record high, while the Nasdaq 100 increased by 0.08% to a 2.25-month peak, indicating strong demand for data storage and chip manufacturing stocks.
- Surge in Metal Prices: Gold and silver prices soared to all-time highs, driving mining stocks higher, with Hecla Mining and Coeur Mining gaining over 8% and 5% respectively, reflecting strong investor interest in precious metals.
- Economic Data Focus: The market is set to focus on upcoming economic data releases, including December CPI and PPI, which are expected to influence future monetary policy amid political pressures on the Federal Reserve.
- Earnings Season Kickoff: S&P 500 companies are projected to see an 8.4% earnings growth in Q4, while excluding the Magnificent Seven tech giants, earnings growth is expected at 4.6%, providing crucial signals for investors.
See More
Trump Pressures Fed, Credit Card Stocks Slide Amid Legal Threats
- Market Volatility: The S&P 500 Index rose by 0.28%, the Dow Jones Industrial Average increased by 0.15%, and the Nasdaq 100 climbed by 0.55%, despite heightened concerns over Fed independence due to the Trump administration's attacks, leading to a 'Sell America' sentiment in US asset markets.
- Credit Card Companies Hit: President Trump stated that credit card lenders would be 'in violation of the law' if they do not cap interest rates at 10% for one year, causing significant declines in credit card and bank stocks, with Synchrony Financial down over 7% and Capital One Financial down over 6%.
- Gold Prices Surge: Gold and silver prices soared to new all-time highs, driving mining stocks higher, with Hecla Mining up over 8% and Coeur Mining up over 6%, reflecting strong investor demand for safe-haven assets amid market uncertainty.
- Fed Faces Legal Threats: Fed Chair Powell indicated that the threat of criminal charges stems from the Fed's refusal to comply with Trump's calls for lower interest rates, which could impact future policy decisions and create greater uncertainty in market expectations regarding interest rate movements.
See More
Trump Pressures Fed, Stock Markets Dip Slightly Amid Concerns
- Market Pressure Intensifies: The S&P 500, Dow Jones, and Nasdaq 100 indices fell by 0.03%, 0.18%, and 0.07% respectively, as Trump's administration's attacks on the Federal Reserve raised concerns about its independence, indicating a bearish sentiment in U.S. asset markets.
- Gold and Silver Surge: Following Fed Chair Powell's warning of potential criminal charges, gold and silver prices soared to new all-time highs, boosting mining stocks and reflecting a growing demand for safe-haven assets amid market uncertainty.
- Credit Card Companies Hit: Trump's statement that credit card lenders would be
See More
Trump's Pressure on Fed Leads to Broad Market Decline
- Market Pressure Intensifies: The S&P 500 Index fell by 0.23%, the Dow Jones Industrial Average by 0.58%, and the Nasdaq 100 by 0.27% due to increased concerns over Fed independence stemming from the Trump administration's attacks, indicating a bearish sentiment among investors.
- Gold Prices Surge: Following Fed Chair Powell's comments about facing criminal indictment, gold and silver prices reached all-time highs, reflecting a strong demand for safe-haven assets and potentially leading to capital outflows from the stock market.
- Credit Card Companies Hit: Trump's statement that credit card lenders would violate the law if they do not cap interest rates at 10% caused Synchrony Financial's stock to drop over 7%, highlighting the direct impact of policy risks on financial stocks.
- Economic Data Focus: The market is set to closely monitor upcoming economic data, including December CPI and PPI, which are expected to influence the Fed's monetary policy direction and further exacerbate market uncertainties.
See More
ANI Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Announcement: ANI Pharmaceuticals CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:00 p.m. PT, showcasing the company's latest advancements in the biopharmaceutical sector.
- Webcast Availability: The live and archived webcast will be accessible from the company's website under the Investors section, allowing investors to access the content for 30 days, thereby enhancing transparency and investor engagement.
- Company Mission: ANI Pharmaceuticals is committed to its mission of 'Serving Patients, Improving Lives' by developing and commercializing innovative, high-quality therapeutics, particularly in the rare disease sector, driving sustainable growth.
- Business Focus: The company emphasizes innovative products in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, leveraging R&D expertise and U.S.-based manufacturing to enhance its competitive position in the market.
See More
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reflecting $2.52 Million Loss
- Position Change: Stonepine Capital reported in its latest SEC filing that it fully exited its position in ANI Pharmaceuticals, selling 38,597 shares for a total transaction value of $2.52 million, indicating a cautious outlook on the company's future performance.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has surged 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase, showcasing the company's strong market presence.
- Financial Overview: ANI Pharmaceuticals boasts a market capitalization of $1.85 billion, with trailing twelve-month revenue of $826.89 million and net income of $40.57 million, reflecting the company's sustained profitability in the specialty pharmaceuticals sector.
- Future Outlook: Management has raised full-year revenue guidance to $873 million, with rare disease therapies expected to drive approximately half of total sales by 2025, highlighting the company's growth potential in niche therapeutic areas.
See More
S&P 500 Hits Record High as Data Storage Stocks Lead Gains
- Market Recovery: The S&P 500 index rose by 0.16% to reach a record high, while the Nasdaq 100 increased by 0.08% to a 2.25-month peak, indicating strong demand for data storage and chip manufacturing stocks.
- Surge in Metal Prices: Gold and silver prices soared to all-time highs, driving mining stocks higher, with Hecla Mining and Coeur Mining gaining over 8% and 5% respectively, reflecting strong investor interest in precious metals.
- Economic Data Focus: The market is set to focus on upcoming economic data releases, including December CPI and PPI, which are expected to influence future monetary policy amid political pressures on the Federal Reserve.
- Earnings Season Kickoff: S&P 500 companies are projected to see an 8.4% earnings growth in Q4, while excluding the Magnificent Seven tech giants, earnings growth is expected at 4.6%, providing crucial signals for investors.
See More
Trump Pressures Fed, Credit Card Stocks Slide Amid Legal Threats
- Market Volatility: The S&P 500 Index rose by 0.28%, the Dow Jones Industrial Average increased by 0.15%, and the Nasdaq 100 climbed by 0.55%, despite heightened concerns over Fed independence due to the Trump administration's attacks, leading to a 'Sell America' sentiment in US asset markets.
- Credit Card Companies Hit: President Trump stated that credit card lenders would be 'in violation of the law' if they do not cap interest rates at 10% for one year, causing significant declines in credit card and bank stocks, with Synchrony Financial down over 7% and Capital One Financial down over 6%.
- Gold Prices Surge: Gold and silver prices soared to new all-time highs, driving mining stocks higher, with Hecla Mining up over 8% and Coeur Mining up over 6%, reflecting strong investor demand for safe-haven assets amid market uncertainty.
- Fed Faces Legal Threats: Fed Chair Powell indicated that the threat of criminal charges stems from the Fed's refusal to comply with Trump's calls for lower interest rates, which could impact future policy decisions and create greater uncertainty in market expectations regarding interest rate movements.
See More
Trump Pressures Fed, Stock Markets Dip Slightly Amid Concerns
- Market Pressure Intensifies: The S&P 500, Dow Jones, and Nasdaq 100 indices fell by 0.03%, 0.18%, and 0.07% respectively, as Trump's administration's attacks on the Federal Reserve raised concerns about its independence, indicating a bearish sentiment in U.S. asset markets.
- Gold and Silver Surge: Following Fed Chair Powell's warning of potential criminal charges, gold and silver prices soared to new all-time highs, boosting mining stocks and reflecting a growing demand for safe-haven assets amid market uncertainty.
- Credit Card Companies Hit: Trump's statement that credit card lenders would be
See More
Trump's Pressure on Fed Leads to Broad Market Decline
- Market Pressure Intensifies: The S&P 500 Index fell by 0.23%, the Dow Jones Industrial Average by 0.58%, and the Nasdaq 100 by 0.27% due to increased concerns over Fed independence stemming from the Trump administration's attacks, indicating a bearish sentiment among investors.
- Gold Prices Surge: Following Fed Chair Powell's comments about facing criminal indictment, gold and silver prices reached all-time highs, reflecting a strong demand for safe-haven assets and potentially leading to capital outflows from the stock market.
- Credit Card Companies Hit: Trump's statement that credit card lenders would violate the law if they do not cap interest rates at 10% caused Synchrony Financial's stock to drop over 7%, highlighting the direct impact of policy risks on financial stocks.
- Economic Data Focus: The market is set to closely monitor upcoming economic data, including December CPI and PPI, which are expected to influence the Fed's monetary policy direction and further exacerbate market uncertainties.
See More
ANI Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Announcement: ANI Pharmaceuticals CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:00 p.m. PT, showcasing the company's latest advancements in the biopharmaceutical sector.
- Webcast Availability: The live and archived webcast will be accessible from the company's website under the Investors section, allowing investors to access the content for 30 days, thereby enhancing transparency and investor engagement.
- Company Mission: ANI Pharmaceuticals is committed to its mission of 'Serving Patients, Improving Lives' by developing and commercializing innovative, high-quality therapeutics, particularly in the rare disease sector, driving sustainable growth.
- Business Focus: The company emphasizes innovative products in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, leveraging R&D expertise and U.S.-based manufacturing to enhance its competitive position in the market.
See More
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reflecting $2.52 Million Loss
- Position Change: Stonepine Capital reported in its latest SEC filing that it fully exited its position in ANI Pharmaceuticals, selling 38,597 shares for a total transaction value of $2.52 million, indicating a cautious outlook on the company's future performance.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has surged 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase, showcasing the company's strong market presence.
- Financial Overview: ANI Pharmaceuticals boasts a market capitalization of $1.85 billion, with trailing twelve-month revenue of $826.89 million and net income of $40.57 million, reflecting the company's sustained profitability in the specialty pharmaceuticals sector.
- Future Outlook: Management has raised full-year revenue guidance to $873 million, with rare disease therapies expected to drive approximately half of total sales by 2025, highlighting the company's growth potential in niche therapeutic areas.
See More
